Log In
Print
BCIQ
Print
Print this Print this
 

SAR100842

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionLPA-1 and LPA-3 receptor antagonist
Molecular Target
Mechanism of ActionLysophosphatidic acid receptor 1 (LPAR1) (EDG2) antagonist; Lysophosphatidic acid receptor 3 (LPAR3) antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationScleroderma
Indication DetailsTreat skin manifestation of scleroderma; Treat systemic sclerosis
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today